|1.||Albouy, M: 1 article (08/2008)|
|2.||Eun, H M: 1 article (08/2008)|
|3.||Sanquer, A: 1 article (08/2008)|
|4.||Maynard, L: 1 article (08/2008)|
|5.||Cordes, E K: 1 article (01/2001)|
|6.||Hoppen, H O: 1 article (01/2001)|
|7.||Lange, K: 1 article (01/2001)|
|8.||Günzel-Apel, A R: 1 article (01/2001)|
|1.||Body Weight (Weight, Body)
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
08/09/2008 - "Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs."
08/01/1998 - "Delmadinone acetate was administered to six normal male dogs and seven dogs with benign prostatic hyperplasia at recommended dose rates (1.5 mg/kg subcutaneously at 0, 1 and 4 weeks). "
08/09/2008 - "A multicentre randomised clinical trial was performed to compare the therapeutic potential of osaterone acetate with that of delmadinone acetate in the treatment of benign prostatic hyperplasia in dogs. "
08/01/1998 - "To characterise the effects of delmadinone acetate on the pituitary-adrenal axis, glucose tolerance and growth hormone concentration in normal male dogs and dogs with benign prostatic hyperplasia. "
|2.||Growth Hormone (Somatotropin)